WebJul 20, 2024 · Lp(a) HORIZON is a global, multicenter, double-blind, placebo-controlled pivotal Phase 3 study conducted by Novartis. The study is designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a) with 80 mg of pelacarsen administered monthly via subcutaneous administration. WebSep 22, 2024 · Sandoz’s Denosumab Meets Primary Endpoints in Phase 3 Trial. The biosimilar matches Prolia in efficacy, immunogenicity, pharmacodynamics, and …
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint …
WebOct 26, 2024 · Media Release. Novartis announced the company’s financial results for the third quarter of 2024. English (PDF 0.3 MB) Deutsch (PDF 0.3 MB) Français (PDF 0.4 … WebRecruiting Clinical Trials Novartis Home Clinical Trials Recruiting Clinical Trials Phase Not Applicable Phase 1 Phase 2 Phase 3 Phase 4 Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua & Barbuda Argentina Armenia Aruba Ascension Island Australia Austria Azerbaijan Bahamas Bahrain Bangladesh buzzi phone booth
SPR1NT Trial Data Suggest Promise for Zolgensma in SMA With 3 …
WebJul 17, 2024 · Go to Brief Summary: This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and … WebMar 27, 2024 · EAST HANOVER, N.J., March 27, 2024 /PRNewswire/ -- Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali ® (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative … WebMar 27, 2024 · Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. ... Novartis Kisqali® Phase … cetaphil 24hr hydration